Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269381 | 0.94 | PIK3CD (0.38) | KCNH2SCN5ASCN9APIK3CDHTR2C | |
| SCHEMBL31269307 | 0.94 | PIK3CD (0.34) | KCNH2PIK3CDSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL30983481 | 0.93 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268925 | 0.93 | KCNH2 (0.38) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268763 | 0.91 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268839 | 0.91 | KCNH2 (0.36) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268952 | 0.91 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269260 | 0.91 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269196 | 0.90 | KCNH2 (0.35) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268847 | 0.90 | KCNH2 (0.36) | KCNH2SCN5ASCN9APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |